HLS Therapeutics (TSE:HLS) Sets New 12-Month High - Here's Why

Key Points

• HLS Therapeutics Inc. reached a new 52-week high of C$5.75, with a trading volume of 5,701 shares.
• Raymond James Financial upgraded HLS Therapeutics from a "hold" to a "moderate buy" rating and raised their price target from C$5.00 to C$6.00.
• The company specializes in the acquisition and commercialization of branded pharmaceutical products in the North American market, focusing on treatments for CNS and cardiovascular specialties.

Shares of HLS Therapeutics Inc. (TSE:HLS - Get Free Report) reached a new 52-week high on Tuesday . The stock traded as high as C$5.72 and last traded at C$5.75, with a volume of 5701 shares traded. The stock had previously closed at C$5.65.

Analysts Set New Price Targets

Separately, Raymond James Financial upgraded shares of HLS Therapeutics from a "hold" rating to a "moderate buy" rating and boosted their price objective for the stock from C$5.00 to C$6.00 in a research report on Thursday, August 21st. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of C$5.00.

HLS Therapeutics Stock Up 1.9%

The firm's 50-day simple moving average is C$5.29 and its 200 day simple moving average is C$4.86. The company has a market cap of C$180.83 million, a P/E ratio of -12.00 and a beta of 0.65. The company has a debt-to-equity ratio of 86.50, a quick ratio of 1.01 and a current ratio of 1.56.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.